Maple M. Fung

Adamis Pharmaceuticals (United States) — United States

Medicine · Health Sciences

23h-index2.3kcitations78works2.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Gout, Hyperuricemia, Uric Acid(16), Receptor Mechanisms and Signaling(15), Blood Pressure and Hypertension Studies(10), Cellular transport and secretion(7), Hormonal Regulation and Hypertension(6)

Publications78 total

Interim Phase 1 Study Results of ADX-038: A Novel siRNA Against Complement Factor B, and Next Steps in IgAN and C3 Glomerulopathy (C3G)
Journal of the American Society of Nephrology·2025
Prevalence of Mild Autonomous Cortisol Secretion in Adrenal Incidentalomas and the Significance of Subcentimeter Adrenal Nodules: A Single-Center Cohort Study
Endocrine Practice·2025· 1 cited
Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis
Lara D. Veeken·2024· 6 citedOpen Access
Utility of zero echo time (ZTE) sequence for assessing bony lesions of skull base and calvarium
Clinical Radiology·2024· 3 citedOpen Access
EQUALISE Type B: Clinical Results of Itolizumab, a Novel Anti-CD6 Therapy, in Subjects with Lupus Nephritis
Journal of the American Society of Nephrology·2023· 2 cited
Final Safety and Efficacy Results from Equate, an Open-Label Study Evaluating Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Acute Graft-Versus-Host Disease
Transplantation and Cellular Therapy·2023· 2 cited
Predictors of Patient and Physician Assessments of Gout Control
Arthritis Care & Research·2022· 5 citedOpen Access
Itolizumab, a Novel Targeted Anti-CD6 Therapy, Induces Cleavage of Cell Surface CD6 and Rapid Onset of Efficacy in Subjects with Newly Diagnosed Acute Graft-Versus-Host Disease
Transplantation and Cellular Therapy·2022
Updated Interim Results from the Equate Study: Preliminary Safety and Efficacy of Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Acute Graft-Versus-Host Disease
Transplantation and Cellular Therapy·2022· 1 cited
Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease
Blood·2021· 3 cited
Itolizumab, a Novel Anti-CD6 Antibody, in Systemic Lupus Patients with Proteinuria: An Interim Subgroup Analysis from EQUALISE, a Phase 1b Study
Journal of the American Society of Nephrology·2021
Itolizumab, a Novel Anti-CD6 Therapy, in Systemic Lupus Erythematosus Patients: Interim Safety Results from the Phase 1b EQUALISE Dose-Escalation Study
Journal of the American Society of Nephrology·2021· 1 cited
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P183-P186)
Bone Marrow Transplantation·2021· 1 citedOpen Access
Radiologic evidence of symmetric and polyarticular monosodium urate crystal deposition in gout – A cluster pattern analysis of dual-energy CT
Seminars in Arthritis and Rheumatism·2019· 17 citedOpen Access
Concurrent validity of provisional remission criteria for gout: a dual-energy CT study
Arthritis Research & Therapy·2019· 22 citedOpen Access
PS-106-An international, randomized, placebo-controlled phase 2 trial demonstrates novel effects of DGAT2 antisense inhibition in reducing steatosis without causing hypertriglyceridemia in T2DM patients
Journal of Hepatology·2019· 7 cited
Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
Arthritis Research & Therapy·2019· 24 citedOpen Access
Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol
Annals of the Rheumatic Diseases·2017· 63 citedOpen Access
Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study
Lara D. Veeken·2017· 113 citedOpen Access
Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
Arthritis & Rheumatology·2017· 150 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Daniel T. O’Connor(29), Fangwen Rao(22), Manjula Mahata(18), Michael G. Ziegler(14), Kuixing Zhang(14), Sushil K. Mahata(13), Rany M. Salem(12), Scott Baumgartner(11), Caroline M. Nievergelt(11), Nicholas J. Schork(9), Chris Storgard(8), Nicola Dalbeth(8), Bruce A. Hamilton(8), Jeff Kopicko(7), Nihar Bhakta(7), Srikrishna Khandrika(7), Jill Waalen(7), Scott Adler(6), Mats Stridsberg(6), Laurent Taupenot(6)